Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma
Condition:   Non Hodgkin's Lymphoma Intervention:   Drug: PEG-rhG-CSF Sponsors:   CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.;   Hebei Medical University Fourth Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 4, 2020 Category: Research Source Type: clinical trials

A Retrospective Cohort Study: Influence of MTHFR C677T and A1298C Polymorphisms on the Survival of Pediatric Patients With Non-Hodgkin's Lymphoma
Condition:   Pediatric Non-Hodgkin Lymphoma Intervention:   Sponsor:   Sun Yat-sen University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2020 Category: Research Source Type: clinical trials

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
Condition:   Diffuse Large B-Cell Lymphoma (DLBCL) Intervention:   Biological: Tisagenlecleucel Sponsor:   Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 2, 2020 Category: Research Source Type: clinical trials

Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: a structured summary of a study protocol for a randomised controlled trial
This study is performed in five academic centres affiliated to Mashhad University of Medical Sciences, Mashhad, Iran.Intervention and comparatorPatients are randomly assigned to two groups; one being given hydroxychloroquine and the other is given placebo. During two months of treatment, the two groups are treated with either hydroxychloroquine (Amin ® Pharmaceutical Company, Isfahan, Iran) or placebo (identical in terms of shape, colour, smell) as a single 200 mg tablet every other day. Patients will be monitored for COVID-19 symptoms during the follow-up period. If signs or symptoms occur (fever, cough, shortness of ...
Source: Trials - June 26, 2020 Category: Research Source Type: clinical trials

Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma
Condition:   Non-hodgkin's Lymphoma Intervention:   Biological: CD19 CAR-T Sponsors:   Hebei Senlang Biotechnology Inc., Ltd.;   Beijing Ludaopei Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 25, 2020 Category: Research Source Type: clinical trials

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
Condition:   NHL Intervention:   Drug: IM19 CAR-T Cells Sponsor:   Beijing Immunochina Medical Science& Technology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 19, 2020 Category: Research Source Type: clinical trials

A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma
Condition:   Non Hodgkin Lymphoma Intervention:   Sponsor:   Ruijin Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 17, 2020 Category: Research Source Type: clinical trials